Glaxo, Boehringer Ingelheim Agree to Expand Anti-HIV Licensing in South Africa

Law360, New York (December 10, 2003, 12:00 AM EST) -- GlaxoSmithKline and Boehringer Ingelheim agreed to allow the widespread manufacture of generic versions of their patented AIDS drugs in South Africa, according to news reports.

In an out-of-court settlement with the country's Treatment Action Campaign (TAC), the companies on Wednesday said they would grant more licences to generic firms to produce and import antiretroviral drugs which fight the spread of the HIV virus.

South Africa has more people living with HIV/AIDS than any other country in the world: an estimated 5.3 million, equal to to 13%...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.